MET and breast cancer: Considering that c-Met amplification showed a high sensitivity for crizotinib in NSCLC cell lines but no sensitivity for cisplatin [53], other BC cell lines should be included for evaluating the association between c-Met amplification level and crizotinib sensitivity.